NEW YORK (360Dx) — Akers Biosciences announced on Wednesday that its board has begun reviewing strategic options for the company — including possible business combinations — in a bid to boost shareholder value.

According to Akers, it will continue its current business activities during the review, and it will not provide updates on the process until it is completed or "further disclosure is deemed appropriate."

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.